Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen

NCT04837196 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignancies
Advanced Cancer

Interventions

DRUG: ASP7517
DRUG: Pembrolizumab

Sponsor

Astellas Pharma Global Development, Inc.